• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

8.400 -0.080 (-0.94%)
Streaming Delayed Price Updated: 12:32 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 Next >
News headline image
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 18, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
December 10, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
December 01, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
December 01, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
November 12, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 03, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
October 22, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
September 03, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
August 13, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
July 29, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Private Placement Financing
July 28, 2025
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Private Placement Financing
July 22, 2025
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
July 21, 2025
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends “FOCUSfactor” Exploding Across North America – More Stocks Inside
July 14, 2025
Via AB Newswire
News headline image
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 17, 2025
Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ET 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
May 12, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
March 31, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
March 24, 2025
Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
March 13, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
March 11, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
February 25, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Issues Letter to Shareholders
January 13, 2025
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
January 10, 2025
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
November 26, 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
November 14, 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 12, 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
October 30, 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap